![Peter Steiner](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Peter Steiner
Fondatore presso PreComb Therapeutics AG
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Klaus Mauch | M | - |
Insilico Biotechnology AG
![]() Insilico Biotechnology AG Packaged SoftwareTechnology Services Part of Yokogawa Electric Corp., Insilico Biotechnology AG is a German company that develops software for biotechnology. The company is based in Stuttgart, Germany. The company was founded in 2001 by Klaus Mauch. Klaus Mauch has been the CEO since 2001. Insilico Biotechnology was acquired by Yokogawa Electric Corp. on November 02, 2021 for $30.14 million. | 23 anni |
Jens M. Kelm | M | - |
PreComb Therapeutics AG
![]() PreComb Therapeutics AG Pharmaceuticals: MajorHealth Technology PreComb Therapeutics AG is a Swiss company that specializes in functional precision medicine for oncology and cancer. The company is based in Hombrechtikon, Switzerland. The company uses organoid and predictive technologies, as well as AI and data mining, to guide therapy and automate processes. The company also works in immune oncology and collaborate with other organizations such as 2curex, Xilis, USZ, DKFZ, and NCT. The company was founded in 2018 by Peter Steiner and Jens M. Kelm, with Jens M. Kelm serving as CEO since then. | - |
Johannes Roth | M | 44 |
Insilico Biotechnology AG
![]() Insilico Biotechnology AG Packaged SoftwareTechnology Services Part of Yokogawa Electric Corp., Insilico Biotechnology AG is a German company that develops software for biotechnology. The company is based in Stuttgart, Germany. The company was founded in 2001 by Klaus Mauch. Klaus Mauch has been the CEO since 2001. Insilico Biotechnology was acquired by Yokogawa Electric Corp. on November 02, 2021 for $30.14 million. | - |
Patrick Aisher | M | 53 |
PreComb Therapeutics AG
![]() PreComb Therapeutics AG Pharmaceuticals: MajorHealth Technology PreComb Therapeutics AG is a Swiss company that specializes in functional precision medicine for oncology and cancer. The company is based in Hombrechtikon, Switzerland. The company uses organoid and predictive technologies, as well as AI and data mining, to guide therapy and automate processes. The company also works in immune oncology and collaborate with other organizations such as 2curex, Xilis, USZ, DKFZ, and NCT. The company was founded in 2018 by Peter Steiner and Jens M. Kelm, with Jens M. Kelm serving as CEO since then. | - |
Bertram Layer | M | - |
Insilico Biotechnology AG
![]() Insilico Biotechnology AG Packaged SoftwareTechnology Services Part of Yokogawa Electric Corp., Insilico Biotechnology AG is a German company that develops software for biotechnology. The company is based in Stuttgart, Germany. The company was founded in 2001 by Klaus Mauch. Klaus Mauch has been the CEO since 2001. Insilico Biotechnology was acquired by Yokogawa Electric Corp. on November 02, 2021 for $30.14 million. | - |
Lothar Terfloth | M | - |
Insilico Biotechnology AG
![]() Insilico Biotechnology AG Packaged SoftwareTechnology Services Part of Yokogawa Electric Corp., Insilico Biotechnology AG is a German company that develops software for biotechnology. The company is based in Stuttgart, Germany. The company was founded in 2001 by Klaus Mauch. Klaus Mauch has been the CEO since 2001. Insilico Biotechnology was acquired by Yokogawa Electric Corp. on November 02, 2021 for $30.14 million. | - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Thomas O. Hecht | M | 73 |
ESBATech, a Novartis Co. GmbH
![]() ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | 5 anni |
James J. Egan | M | 73 |
ESBATech, a Novartis Co. GmbH
![]() ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | 3 anni |
Martin Gertsch | M | 59 |
ESBATech, a Novartis Co. GmbH
![]() ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | 2 anni |
Peter Lichtlen | M | 56 |
ESBATech, a Novartis Co. GmbH
![]() ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | 9 anni |
Anne Schmidt | M | - |
ESBATech, a Novartis Co. GmbH
![]() ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | - |
Jürgen E. Bader | M | - |
ESBATech, a Novartis Co. GmbH
![]() ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | - |
Rouven Bingel-Erlenmeyer | M | - |
ESBATech, a Novartis Co. GmbH
![]() ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | - |
Ulrich Bauer | M | - |
ESBATech, a Novartis Co. GmbH
![]() ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | - |
Christian Leisner | M | - |
ESBATech, a Novartis Co. GmbH
![]() ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | - |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Svizzera | 11 | 73.33% |
Germania | 4 | 26.67% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Peter Steiner
- Contatti personali